215 related articles for article (PubMed ID: 32148142)
81. Salvage chemotherapy and autologous stem cell transplantation are inferior for relapsed or refractory primary mediastinal large B-cell lymphoma compared with diffuse large B-cell lymphoma.
Kuruvilla J; Pintilie M; Tsang R; Nagy T; Keating A; Crump M
Leuk Lymphoma; 2008 Jul; 49(7):1329-36. PubMed ID: 18604722
[TBL] [Abstract][Full Text] [Related]
82. A prognostic model predicting autologous transplantation outcomes in children, adolescents and young adults with Hodgkin lymphoma.
Satwani P; Ahn KW; Carreras J; Abdel-Azim H; Cairo MS; Cashen A; Chen AI; Cohen JB; Costa LJ; Dandoy C; Fenske TS; Freytes CO; Ganguly S; Gale RP; Ghosh N; Hertzberg MS; Hayashi RJ; Kamble RT; Kanate AS; Keating A; Kharfan-Dabaja MA; Lazarus HM; Marks DI; Nishihori T; Olsson RF; Prestidge TD; Rolon JM; Savani BN; Vose JM; Wood WA; Inwards DJ; Bachanova V; Smith SM; Maloney DG; Sureda A; Hamadani M
Bone Marrow Transplant; 2015 Nov; 50(11):1416-23. PubMed ID: 26237164
[TBL] [Abstract][Full Text] [Related]
83. Brentuximab Vedotin in Transplant-Naïve Relapsed/Refractory Hodgkin Lymphoma: Experience in 30 Patients.
Zinzani PL; Pellegrini C; Cantonetti M; Re A; Pinto A; Pavone V; Rigacci L; Celli M; Broccoli A; Argnani L; Pulsoni A
Oncologist; 2015 Dec; 20(12):1413-6. PubMed ID: 26500229
[TBL] [Abstract][Full Text] [Related]
84. ESHAP as salvage therapy for relapsed or refractory Hodgkin's lymphoma.
Labrador J; Cabrero-Calvo M; Pérez-López E; Mateos MV; Vázquez L; Caballero MD; García-Sanz R
Ann Hematol; 2014 Oct; 93(10):1745-53. PubMed ID: 24863692
[TBL] [Abstract][Full Text] [Related]
85. Management of relapsed and refractory classical Hodgkin lymphoma in children and adolescents.
Daw S; Wynn R; Wallace H
Br J Haematol; 2011 Feb; 152(3):249-60. PubMed ID: 21133886
[TBL] [Abstract][Full Text] [Related]
86. Salvage therapy in Hodgkin's lymphoma.
Mendler JH; Friedberg JW
Oncologist; 2009 Apr; 14(4):425-32. PubMed ID: 19342476
[TBL] [Abstract][Full Text] [Related]
87. Novel regimens prior to autologous stem cell transplantation for the management of adults with relapsed/refractory non-Hodgkin lymphoma and Hodgkin lymphoma: alternatives to BEAM conditioning.
Isidori A; Christofides A; Visani G
Leuk Lymphoma; 2016 Nov; 57(11):2499-509. PubMed ID: 27243412
[TBL] [Abstract][Full Text] [Related]
88. Treatment outcome in children and adolescents with relapsed Hodgkin lymphoma--results of the UK HD3 relapse treatment strategy.
Shankar A; Hayward J; Kirkwood A; McCarthy K; Hewitt M; Morland B; Daw S
Br J Haematol; 2014 May; 165(4):534-44. PubMed ID: 24754633
[TBL] [Abstract][Full Text] [Related]
89. [Salvage therapy in relapsed or refractory malignant lymphoma].
Kashimura T; Murohashi I
Nihon Rinsho; 2000 Mar; 58(3):699-703. PubMed ID: 10741149
[TBL] [Abstract][Full Text] [Related]
90. How to choose first salvage therapy in Hodgkin lymphoma: traditional chemotherapy vs novel agents.
Driessen J; Tonino SH; Moskowitz AJ; Kersten MJ
Hematology Am Soc Hematol Educ Program; 2021 Dec; 2021(1):240-246. PubMed ID: 34889399
[TBL] [Abstract][Full Text] [Related]
91. Current approaches to the management of pediatric Hodgkin lymphoma.
Freed J; Kelly KM
Paediatr Drugs; 2010 Apr; 12(2):85-98. PubMed ID: 20218745
[TBL] [Abstract][Full Text] [Related]
92. Autologous stem cell transplantation for patients with active Hodgkin's lymphoma: long-term outcome of 61 patients from a single institution.
Martínez C; Salamero O; Arenillas L; Duque J; López-Guillermo A; Rovira M; Urbano-Ispízua A; Fernández-Avilés F; Carreras E; Montserrat E
Leuk Lymphoma; 2007 Oct; 48(10):1968-75. PubMed ID: 17917965
[TBL] [Abstract][Full Text] [Related]
93. Effectiveness of high dose chemoradiotherapy and autologous stem cell transplantation for patients with biopsy-proven primary refractory Hodgkin's disease.
Moskowitz CH; Kewalramani T; Nimer SD; Gonzalez M; Zelenetz AD; Yahalom J
Br J Haematol; 2004 Mar; 124(5):645-52. PubMed ID: 14871252
[TBL] [Abstract][Full Text] [Related]
94. Involved field radiation therapy following high dose chemotherapy and autologous stem cell transplant benefits local control and survival in refractory or recurrent Hodgkin lymphoma.
Biswas T; Culakova E; Friedberg JW; Kelly JL; Dhakal S; Liesveld J; Phillips GL; Constine LS
Radiother Oncol; 2012 Jun; 103(3):367-72. PubMed ID: 22398312
[TBL] [Abstract][Full Text] [Related]
95. PD-1 blockade with pembrolizumab for classical Hodgkin lymphoma after autologous stem cell transplantation.
Armand P; Chen YB; Redd RA; Joyce RM; Bsat J; Jeter E; Merryman RW; Coleman KC; Dahi PB; Nieto Y; LaCasce AS; Fisher DC; Ng SY; Odejide OO; Freedman AS; Kim AI; Crombie JL; Jacobson CA; Jacobsen ED; Wong JL; Patel SS; Ritz J; Rodig SJ; Shipp MA; Herrera AF
Blood; 2019 Jul; 134(1):22-29. PubMed ID: 30952672
[TBL] [Abstract][Full Text] [Related]
96. Autologous stem cell transplantation after anti-PD-1 therapy for multiply relapsed or refractory Hodgkin lymphoma.
Merryman RW; Redd RA; Nishihori T; Chavez J; Nieto Y; Darrah JM; Rao U; Byrne MT; Bond DA; Maddocks KJ; Spinner MA; Advani RH; Ballard HJ; Svoboda J; Singh AK; McGuirk JP; Modi D; Ramchandren R; Romancik J; Cohen JB; Frigault MJ; Chen YB; Serritella AV; Kline J; Ansell S; Nathan S; Rahimian M; Joyce RM; Shah M; David KA; Park S; Beaven AW; Habib A; Bachanova V; Nakhoda S; Khan N; Lynch RC; Smith SD; Ho VT; LaCasce A; Armand P; Herrera AF
Blood Adv; 2021 Mar; 5(6):1648-1659. PubMed ID: 33710337
[TBL] [Abstract][Full Text] [Related]
97. High-dose therapy and autologous stem cell transplantation for chemoresistant Hodgkin lymphoma: the Seattle experience.
Gopal AK; Metcalfe TL; Gooley TA; Pagel JM; Petersdorf SH; Bensinger WI; Holmberg L; Maloney DG; Press OW
Cancer; 2008 Sep; 113(6):1344-50. PubMed ID: 18623377
[TBL] [Abstract][Full Text] [Related]
98. Second autologous stem cell transplantation for relapsed/refractory Hodgkin lymphoma after a previous autograft: a study of the lymphoma working party of the EBMT.
Martínez C; Boumendil A; Romejko-Jarosinska J; Anagnostopoulos A; Faber E; Poiré X; Yakoub-Agha I; Akhtar S; Gurman G; Pavone V; Halaburda K; Sousa AB; Ghesquières H; Finel H; Khvedelidze I; Montoto S; Sureda A
Leuk Lymphoma; 2020 Dec; 61(12):2915-2922. PubMed ID: 32654552
[TBL] [Abstract][Full Text] [Related]
99. Post-Transplant Nivolumab Plus Unselected Autologous Lymphocytes in Refractory Hodgkin Lymphoma: A Feasible and Promising Salvage Therapy Associated With Expansion and Maturation of NK Cells.
Guolo F; Minetto P; Pesce S; Ballerini F; Clavio M; Cea M; Frello M; Garibotto M; Greppi M; Bozzo M; Miglino M; Passannante M; Marcolin R; Tedone E; Colombo N; Mangerini R; Bo A; Ruzzenenti MR; Carlier P; Serio A; Luchetti S; Dominietto A; Varaldo R; Candiani S; Agostini V; Ravetti JL; Del Zotto G; Marcenaro E; Lemoli RM
Front Immunol; 2021; 12():753890. PubMed ID: 34804039
[TBL] [Abstract][Full Text] [Related]
100. Salvage regimens for Hodgkin lymphoma.
Cashen AF; Bartlett NL
Clin Adv Hematol Oncol; 2008 Jul; 6(7):517-24. PubMed ID: 18654119
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]